We have recently described a new biological phenomenon, we have termed mesenchymal-endothelial- transition (MEndoT), where scar forming cells in the heart, exhibit plasticity and adopt endothelial cell like fates after cardiac injury. Fibroblast derived endothelial cells contributed to post injury neovascularization and disruption of MEndoT worsened post injury neovascularization and repair. In contrast, augmentation of MEndoT decreased fibrosis and enhanced cardiac repair, demonstrating the potential of MEndoT as a novel therapeutic target in acute heart injury. In more chronic forms of cardiac injury such as cardiac hypertrophy, increased neovascularization is a critical part of the cardiac compensatory response. Enhanced neovascularization is seen in the initial compensatory phase while regression of vasculature and increased fibrosis are seen in the maladaptive phase prior to the development of heart failure. Disruption of neovascularization accelerates and enhanced neovascularization delays or retards the development of heart failure after cardiac hypertrophy. However whether mesenchymal-endothelial-transition occurs in cardiac hypertrophy and can serve as a therapeutic target for delaying or retarding the development of heart failure is not well understood. In this proposal we provide preliminary evidence that mesenchymal-endothelial transition occurs in cardiac hypertrophy and interrogate the physiological role of MEndoT in cardiac hypertrophy with gain and loss of function approaches. Our experiments will provide novel insight into the physiological role of MEndoT in cardiac hypertrophy and potentially identify MEndoT as a novel target for retarding heart failure secondary to cardiac hypertrophy.
We have recently identified a new biological phenomenon called mesenchymal-endothelial-transition where scar forming cells in the heart can coaxed to form endothelial cells and demonstrated this to be a novel strategy for decreasing heart fibrosis after acute injury. In this proposal we will determine whether such a strategy is effective in decreasing scarring in the heart after chronic injury.
| Foulquier, Sébastien; Daskalopoulos, Evangelos P; Lluri, Gentian et al. (2018) WNT Signaling in Cardiac and Vascular Disease. Pharmacol Rev 70:68-141 |
| Yu, Jingyi; Seldin, Marcus M; Fu, Kai et al. (2018) Topological Arrangement of Cardiac Fibroblasts Regulates Cellular Plasticity. Circ Res 123:73-85 |
| Lin, Liang-Yu; Chun Chang, Sunny; O'Hearn, Jim et al. (2018) Systems Genetics Approach to Biomarker Discovery: GPNMB and Heart Failure in Mice and Humans. G3 (Bethesda) 8:3499-3506 |
| Monaghan, Michael G; Holeiter, Monika; Brauchle, Eva et al. (2018) Exogenous miR-29B Delivery Through a Hyaluronan-Based Injectable System Yields Functional Maintenance of the Infarcted Myocardium. Tissue Eng Part A 24:57-67 |
| Pillai, Indulekha C L; Li, Shen; Romay, Milagros et al. (2017) Cardiac Fibroblasts Adopt Osteogenic Fates and Can Be Targeted to Attenuate Pathological Heart Calcification. Cell Stem Cell 20:218-232.e5 |
| Brumm, Andrew J; Nunez, Stefanie; Doroudchi, Mehdi M et al. (2017) Astrocytes Can Adopt Endothelial Cell Fates in a p53-Dependent Manner. Mol Neurobiol 54:4584-4596 |
| Lluri, Gentian; Renella, Pierangelo; Finn, J Paul et al. (2017) Prognostic Significance of Left Ventricular Fibrosis in Patients With Congenital Bicuspid Aortic Valve. Am J Cardiol 120:1176-1179 |
| Seldin, Marcus M; Kim, Eric D; Romay, Milagros C et al. (2017) A systems genetics approach identifiesTrp53inp2as a link between cardiomyocyte glucose utilization and hypertrophic response. Am J Physiol Heart Circ Physiol 312:H728-H741 |
| Murray, Iain R; Baily, James E; Chen, William C W et al. (2017) Skeletal and cardiac muscle pericytes: Functions and therapeutic potential. Pharmacol Ther 171:65-74 |
| Wang, Zhihua; Zhang, Xiao-Jing; Ji, Yan-Xiao et al. (2016) The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med 22:1131-1139 |
